![logo](/logos/SRPT.webp)
Sarepta Therapeutics, Inc.
NASDAQ:SRPT
128.92 (USD) • At close September 6, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Sarepta Therapeutics, Inc. |
Symbool | SRPT |
Munteenheid | USD |
Prijs | 128.92 |
Beurswaarde | 12,294,623,396 |
Dividendpercentage | 0% |
52-weken bereik | 55.25 - 173.25 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Douglas S. Ingram Esq. |
Website | https://www.sarepta.com |
An error occurred while fetching data.
Over Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)